Two-Year Experience with Latanoprostene Bunod in Clinical Practice

Jake E. Radell, Himanshu K. Sharma, Kelsey L. Auyeung, Megan E. Paul, Donna J. Gagliuso, Nisha Chadha, James C. Tsai, Janet B. Serle

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Precis: We retrospectively reviewed records of patients prescribed latanoprostene bunod 0.024% (LBN) to assess its efficacy and safety in a real-world clinical setting. LBN was efficacious in lowering intraocular pressure (IOP) and had a favorable safety profile. Purpose: The aim of this study was to evaluate the usage of LBN, the first topical nitric oxide-donating prostaglandin analog (PGA) for reducing IOP, in clinical practice. Patients and Methods: Retrospective review identified patients prescribed LBN by 5 glaucoma specialists at an academic center from January 2018 to November 2019. Fifty-six patients (102 eyes) met inclusion criteria of an IOP measured at the visit LBN was prescribed and at 2 visits ≥7 days after beginning treatment, with no surgeries, lasers or medication changes during follow-up. Main outcome measures were IOP, number of ocular medications, and adverse effects. Results: IOP (mean±SD, mm Hg) at the visit LBN was prescribed was 16.2±4.3 on 3.2±1.5 glaucoma medications. IOP at most recent visit was 13.7±3.8 on 3.2±1.6 medications. Mean IOP reduction was 2.1±3.5 (P<0.0001) at first follow-up, after 38.7±36.5 days, and 2.5±3.3 (P<0.0001) at last follow-up, after 235.9±160.8 days. Pressure decreased ≥2 mm Hg in 60%, ≥3 mm Hg in 46%, and ≥4 mm Hg in 34% of eyes. All patients received LBN as replacement for a PGA or latanoprost/netarsudil fixed-dose combination. Forty-Three patients remained on LBN throughout the follow-up period. Seven were discontinued for insufficient pressure control, 4 for adverse effects including pain and itching, and 2 for financial reasons. Conclusions: In 2 years of clinical use of LBN, patients exhibited IOP reductions that were statistically significant overall and clinically meaningful in 60% of patients. LBN was well-Tolerated and may be more efficacious than traditional PGAs.

Original languageEnglish
Pages (from-to)776-780
Number of pages5
JournalJournal of Glaucoma
Issue number9
StatePublished - Sep 2021


  • glaucoma
  • latanoprostene bunod
  • open-Angle glaucoma
  • prostaglandin analog


Dive into the research topics of 'Two-Year Experience with Latanoprostene Bunod in Clinical Practice'. Together they form a unique fingerprint.

Cite this